Fragment-Based Hit Screening: Domainex has used its significant experience in drug discovery to develop a high quality unique collection of chemical fragments that will enable drug hunters to explore fragment space and efficiently identify a diverse range of starting points for discovery programmes.
The Domainex fragment collection has considerable advantages over other commercially-available collections of fragments, as it contains a more diverse range of potential interactions without any significant increase in lipophilicity or molecular weight. The consequence of this is that Domainex’s fragment collection is likely to reveal more potent hits.
These hits can then be developed with or without an x-ray crystal structure. The hits identified from this new fragment collection can be efficiently developed into clinical candidates by Domainex’s experienced team of medicinal chemists and computational chemists.